Author

J. H. Rhoades

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Assay:organoid / primary culture· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

C. J. Lengner· 2 shared M. S. Kim· 2 shared N. Li· 2 shared Y. Tian· 2 shared Z. Cramer· 2 shared C. T. Berry· 1 shared D. Mendez· 1 shared F. B. Johnson· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. J. Lengner

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Forward genetic screening in engineered colorectal cancer organoids identifies novel regulators of metastasis

Z. Cramer, X. Wang, N. A. Leu, K. Monaghan, J. H. Rhoades, Y. Tian, J. Rico, D. Mendez, R. Petroni, M. S. Kim, R. Matsuda, M. F. Carrera, I. E. Brodsky, N. Li, C. J. Lengner, M. A. Blanco

The paper uses CRISPR/Cas9 screening in colorectal cancer organoids to identify novel metastasis regulators, finding Ctnna1 and Bcl2l13 as metastasis suppressors.

bioRxiv · Aug 3, 2023 · PreprintCancer Biology

Patient induced pluripotent stem cell-derived hepatostellate organoids establish a basis for liver pathologies in telomeropathies

Y. Choi, M. S. Kim, J. H. Rhoades, N. M. Johnson, C. T. Berry, S. Root, Q. Chen, Y. Tian, R. J. Fernandez, Z. Cramer, S. Adams-Tzivelekidis, N. Li, F. B. Johnson, C. J. Lengner

The paper uses patient-derived iPS cells to model liver pathologies in telomeropathies and identifies AKT suppression as a potential therapeutic target.

bioRxiv · Nov 19, 2021Cell Biology